🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Herta Crauwels

ORCID: 0000-0002-4516-8830
MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study”.

Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study

The Lancet HIV(2024)10.1016/s2352-3018(23)00300-4
N/A
1.1DataRank · unranked
29 citations

Edmund V. Capparelli, Katherine Calabrese, Kristin Baltrusaitis, Mark A. Marzinke, Cynthia McCoig +36 more

Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study

The Lancet HIV(2024)10.1016/s2352-3018(23)00301-6
N/A
0.959DataRank · unranked
26 citations

Jennifer Chapman, Rachel Ohrenschall, Katherine Calabrese, Kristin Baltrusaitis, Barbara Heckman +32 more

Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study

The Lancet HIV(2025)10.1016/s2352-3018(24)00344-8
N/A
0.535DataRank · unranked
12 citations

Kristin Baltrusaitis, Brookie M. Best, Jack Moye, Ellen Townley, Avy Violari +36 more

Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study

Clinical Infectious Diseases(2023)10.1093/cid/ciad020
N/A
0DataRank · unranked
128 citations

Gary Richmond, Giuliano Rizzardini, Anders Thalme, Pierre‐Marie Girard, Alexander Wong +20 more